Advances in stem cell therapy for heart regeneration and repair: Current trends and challenges

Read full text Summarise with VIRAT
Authors: Ciaran O'Brien
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The human heart has long been considered a terminally differentiated organ incapable of meaningful self-repair after ischemic injury, but three decades of stem cell research have begun to challenge that assumption. This research evaluated the comparative efficacy of three cell-based regenerative approaches-bone marrow-derived mesenchymal stem cells (BM-MSCs), cardiac progenitor cells (CPCs), and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs)-in patients with chronic heart failure following myocardial infarction. A total of 169 patients were enrolled across two Irish academic medical centers between February 2022 and October 2024, with 47 receiving BM-MSCs, 39 receiving CPCs, 31 receiving iPSC-CMs, and 52 serving as standard-of-care controls. The primary endpoint was change in left ventricular ejection fraction (LVEF) measured by cardiac magnetic resonance imaging at 24 months. Secondary endpoints included infarct size reduction, MACE-free survival, and functional capacity assessed by six-minute walk distance. IPSC-CM recipients demonstrated the greatest LVEF improvement, rising from a baseline of 33.1% to 52.8% at 24 months (mean gain 19.7 percentage points, p

Fields of Study & Subjects

Mesenchymal stem cell research Congenital heart defects research Tissue Engineering and Regenerative Medicine

Publication details

Journal / source
International Journal of Cardiology Research
Volume
8
Issue
1
Pages
52–58
Publication date
1 January 2026
Language
EN